These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24775603)

  • 1. The multiple facets of drug resistance: one history, different approaches.
    Niero EL; Rocha-Sales B; Lauand C; Cortez BA; de Souza MM; Rezende-Teixeira P; Urabayashi MS; Martens AA; Neves JH; Machado-Santelli GM
    J Exp Clin Cancer Res; 2014 Apr; 33(1):37. PubMed ID: 24775603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can nanomedicines kill cancer stem cells?
    Zhao Y; Alakhova DY; Kabanov AV
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds.
    Ózsvári B; Sotgia F; Lisanti MP
    Aging (Albany NY); 2020 May; 12(11):10162-10179. PubMed ID: 32452826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
    Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
    J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
    Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
    Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cells--important players in tumor therapy resistance.
    Colak S; Medema JP
    FEBS J; 2014 Nov; 281(21):4779-91. PubMed ID: 25158828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Targeting Cancer Stem Cells in Solid Tumors.
    Caldas-Lopes E; Gomez-Arteaga A; Guzman ML
    Curr Stem Cell Res Ther; 2019; 14(5):421-427. PubMed ID: 30806324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
    Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
    Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCM10 compensates for Myc-induced DNA replication stress in breast cancer stem-like cells.
    Murayama T; Takeuchi Y; Yamawaki K; Natsume T; Li M; Marcela RN; Nishimura T; Kogure Y; Nakata A; Tominaga K; Sasahara A; Yano M; Ishikawa S; Ohta T; Ikeda K; Horie-Inoue K; Inoue S; Seki M; Suzuki Y; Sugano S; Enomoto T; Tanabe M; Tada KI; Kanemaki MT; Okamoto K; Tojo A; Gotoh N
    Cancer Sci; 2021 Mar; 112(3):1209-1224. PubMed ID: 33340428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
    Mashima T
    Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Compounds Targeting Cancer Stem Cells: A Promising Resource for Chemotherapy.
    Das PK; Zahan T; Abdur Rakib M; Khanam JA; Pillai S; Islam F
    Anticancer Agents Med Chem; 2019; 19(15):1796-1808. PubMed ID: 31272363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells.
    Colak S; Zimberlin CD; Fessler E; Hogdal L; Prasetyanti PR; Grandela CM; Letai A; Medema JP
    Cell Death Differ; 2014 Jul; 21(7):1170-7. PubMed ID: 24682005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
    Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
    Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer stem cells: the 'Achilles heel' of chemo-resistant tumors.
    Hong IS; Lee HY; Nam JS
    Recent Pat Anticancer Drug Discov; 2015; 10(1):2-22. PubMed ID: 25479037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells.
    Jiang N; Chen W; Zhang JW; Li Y; Zeng XC; Zhang T; Fu BS; Yi HM; Zhang Q
    Mol Med Rep; 2015 Nov; 12(5):7239-46. PubMed ID: 26458963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.